论文部分内容阅读
目的：观察亲溶酶体药物ＩＨＷ２体外净化急性髓细胞白血病骨髓（ＢＭ）进行骨髓移植（ＡＢＭＴ）的临床疗效。方法：用ＩＨＷ２体外净化ＡＢＭＴ患者的ＢＭ，冷冻保存后回输给患者。结果：３例患者输用净化处理的ＢＭ后均成功地恢复造血功能。２例患者移植后至今已分别持续缓解超过３６、３４个月。其中１例患者移植前染色体为４６ＸＹ，ｄｅｌ（１６）（ｑ２２），移植后２个月检测为４６ＸＹ正常染色体核型。１例患者于移植后１９个月复发。结论：初步研究显示亲溶酶体药物ＩＨＷ２，用于临床移植患者是安全可行的，并且对白血病骨髓有一定的净化作用
OBJECTIVE: To observe the clinical efficacy of the in vitro purification of acute myeloid leukemia (BM) using the lysosomal drug IHW2 in bone marrow transplantation (ABMT). Methods: The BM of ABMT patients was purified with IHW2 in vitro and cryopreserved and then transfused to patients. Results: All three patients successfully restored hematopoiesis after decontamination with BM. Two patients have been continuously relieved over 36,34 months after transplantation. One patient had 46XY, del (16) (q22) before transplantation and 46XY normal karyotype at 2 months after transplantation. One patient relapsed 19 months after transplantation. CONCLUSIONS: Preliminary studies have shown that the prodrug lysate IHW2 is safe and feasible for use in clinical transplant recipients and has a decontamination effect on leukemic bone marrow